| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/05/2002 | CA2050623C Ointments containing tricyclic compound |
| 02/05/2002 | CA2045290C Plaster with a high content of softening ingredients |
| 02/03/2002 | CA2353364A1 Aerosol for the treatment or prevention of pain |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008272A2 High affinity soluble interleukin-18 receptor |
| 01/31/2002 | WO2002008268A2 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008239A1 Novel disaccharides with anti-arthritic action |
| 01/31/2002 | WO2002008232A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 01/31/2002 | WO2002008229A1 1-(4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]indole-1-carbonyl(piperazine) derivatives, their preparation and therapeutic application |
| 01/31/2002 | WO2002008222A2 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS |
| 01/31/2002 | WO2002008221A2 Capsaicin receptor ligands |
| 01/31/2002 | WO2002008219A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | WO2002008218A1 Cyclic substituted aminomethyl compounds and medicaments containing said compounds |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008213A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | WO2002008210A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | WO2002008206A1 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors |
| 01/31/2002 | WO2002008203A2 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4 |
| 01/31/2002 | WO2002008201A2 Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4 |
| 01/31/2002 | WO2002008200A2 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 01/31/2002 | WO2002008189A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | WO2002008188A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | WO2002007772A2 Improved oral dosage formulations |
| 01/31/2002 | WO2002007762A1 Human tumor necrosis factor receptors tr21 and tr22 |
| 01/31/2002 | WO2002007759A2 Clostridial toxin derivatives and methods for treating pain |
| 01/31/2002 | WO2002007743A2 Piper methysticum plant extract |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2002007727A1 Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors |
| 01/31/2002 | WO2002007725A1 Method for treating fibrotic diseases or other indications ic |
| 01/31/2002 | WO2002007721A2 Use of cox-2 inhibitors for preventing immunodeficiency |
| 01/31/2002 | WO2002007720A1 Compounds having mif antagonist activity |
| 01/31/2002 | WO2002007712A2 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/31/2002 | WO2002007706A1 Method for coating solid particles with a thermofusible agent, and resulting coated solid particles |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | WO2002007675A2 Omega-conopeptides |
| 01/31/2002 | WO2002007673A2 Calcilytic compounds |
| 01/31/2002 | WO2001078580A3 A method combining inducing hypothermia and administering a therapeutic agent |
| 01/31/2002 | WO2001070682A3 Carbocyclic side chain containing metalloprotease inhibitors |
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001062940A3 New phosphodiesterase type 7b |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001030338A3 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation |
| 01/31/2002 | WO2001022791A3 Controlled release compositions comprising nimesulide |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013459 Process for the preparation of macrocyclic metalloprotease inhibitors |
| 01/31/2002 | US20020013369 Certain 5-alkyl-2arylaminophenylacetic acids and derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013337 For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis |
| 01/31/2002 | US20020013333 As inhibitors of matrix metalloproteinase, for therapy of diseases such as degenerative diseases and certain cancers |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013274 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 01/31/2002 | US20020013257 Use of ligands to GABAB receptors |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012702 Controlled release anti-inflammatory oral formulation and a process for the preparation thereof |
| 01/31/2002 | US20020012679 Process for manufacturing coated gabapentin or pregabalin particles |
| 01/31/2002 | US20020012669 For detecting a genetic abnormality, cancer |
| 01/31/2002 | US20020012664 Combining agent to be tested, antibody or antigen-binding fragment which binds to amino terminal domain of mammalian CC-chemokine receptor 2, mammalian CC-chemokine receptor 2 or ligand-binding variant, measuring binding |
| 01/31/2002 | DE10035144A1 Cyclische Aminosäurederivate Cyclic amino acid derivatives |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2416988A1 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416750A1 Compounds having mif antagonist activity |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416287A1 Omega-conopeptides |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415196A1 Cyclic substituted aminomethyl compounds and medicaments comprising these compounds |
| 01/31/2002 | CA2415131A1 Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2412408A1 Human tumor necrosis factor receptors tr21 and tr22 |
| 01/31/2002 | CA2410683A1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/30/2002 | EP1176146A1 Carbamoyl tetrahydropyridine derivatives |
| 01/30/2002 | EP1176145A1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 01/30/2002 | EP1176144A1 N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists |
| 01/30/2002 | EP1176140A1 Amide compounds and medicinal use thereof |
| 01/30/2002 | EP1175915A1 A method for preparing resinates |
| 01/30/2002 | EP1175913A1 Intramuscular pharmaceutical composition comprising dexibuprofen and uses thereof |
| 01/30/2002 | EP1175504A1 Dna encoding the human vanilloid receptor vr1 |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175445A1 Specific antibodies and antibody fragments for tgfbeta1 |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |